Evidence map›Paper›PMID 35419620›Full record

ArticleHandbook of experimental pharmacology2022

Targeting the Enteroendocrine System for Treatment of Obesity.

Emily L Miedzybrodzka, Fiona M Gribble, Frank Reimann

Abstract read
PubMed Publisher
In one paragraph

Article in Handbook of experimental pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Emily L MiedzybrodzkaWellcome Trust - MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Fiona M GribbleWellcome Trust - MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. fmg23@cam.ac.uk.
Frank ReimannWellcome Trust - MRC Institute of Metabolic Science, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK.
Addenbrooke's Hospital · GBUniversity of Cambridge · GBWellcome/MRC Institute of Metabolic Science · GB

Funding

Medical Research Council MC_UU_00014/3Medical Research Council MC_UU_00014/5
6 · The paper itself

Abstract

Mimetics of the anorexigenic gut hormone glucagon-like peptide 1 (GLP-1) were originally developed as insulinotropic anti-diabetic drugs but also evoke significant weight loss, leading to their recent approval as obesity therapeutics. Co-activation of receptors for GLP-1 and other gut hormones which reduce food intake - peptide YY (PYY

Indexed as

Gastric Inhibitory PolypeptideGastrointestinal HormonesGlucagon-Like Peptide 1HumansObesityPeptide YYWeight LossGastric Inhibitory PolypeptideGastrointestinal HormonesGlucagon-Like Peptide 1Peptide YYCCKDiabetesEnteroendocrineGIPGLP-1Gut hormoneObesityPYY

Identifiers

PMID35419620
OpenAlexW4224016891

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.